SCHEMBL15078355

SCHEMBL15078355

C[C@@H](OC(N)=O)[C@H](O)c1cc(Cl)ccc1Cl

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
EPHX1 P07099 1/20 0.36
RAB9A P51151 1/20 0.35
ALDH1A1 P00352 4/20 0.35
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
GAA P10253 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
TSHR P16473 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
CYP1A2 P05177 1/20 0.33
ABL1 P00519 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GLA P06280 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15078354 1.00 TP53 (0.38) TP53LMNAHTTEPHX1RAB9A
SCHEMBL3435931 0.88 LMNA (0.49) TP53LMNAHTTEPHX1SMN1; SMN2
SCHEMBL3435170 0.88 LMNA (0.49) TP53LMNAHTTEPHX1SMN1; SMN2
SCHEMBL3434952 0.88 LMNA (0.49) TP53LMNAHTTEPHX1SMN1; SMN2
Jbpos-0101 SCHEMBL29982650 0.81 CXCL8 (0.41) CYP1A2
Jbpos-0101 SCHEMBL3437166 0.81 CXCL8 (0.41) CYP1A2
Jbpos-0101 SCHEMBL3437169 0.81 CXCL8 (0.41) CYP1A2
Jbpos-0101 SCHEMBL3435524 0.81 CXCL8 (0.41) CYP1A2
Jbpos-0101 SCHEMBL3437156 0.81 CXCL8 (0.41) CYP1A2
Jbpos-0101 SCHEMBL3435025 0.81 CXCL8 (0.41) CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3423433-B1 SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES BIO PHARM SOLUTIONS CO LTD (KR) 2025-12-17 EP disclosed
EP-2968211-B1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO PHARM SOLUTIONS CO LTD (KR) 2021-05-12 EP disclosed
US-10351519-B2 Sulfamate derivative compounds, processes for preparing them and their uses BIO-PHARM SOLUTIONS CO., LTD. (KR) 2019-07-16 US disclosed
US-10351519-B2 Sulfamate derivative compounds, processes for preparing them and their uses BIO-PHARM SOLUTIONS CO., LTD. (KR) 2019-07-16 US disclosed
EP-3423433-A1 SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES Bio-Pharm Solutions Co., Ltd. (KR) 2019-01-09 EP disclosed
US-9504668-B2 Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-11-29 US disclosed
US-9504668-B2 Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-11-29 US disclosed
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-01-28 US disclosed
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-01-28 US disclosed
US-9029589-B2 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-05-12 US disclosed
US-9029589-B2 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-05-12 US disclosed
WO-2014142519-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2014-09-18 WO disclosed
WO-2013100566-A1 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-07-04 WO disclosed
US-20130165509-A1 PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-06-27 US disclosed
US-20130165509-A1 PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10351519-B2 Sulfamate derivative compounds, processes for preparing them and their uses STS, SULT2A1, SULT1A1 TP53 4821/4885LMNA 3980/4885HTT 77/4885
US-20130165509-A1 PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME MYLK, PDE3A, TNNC1 TP53 4111/4885LMNA 1572/4885HTT 762/4885
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME SCN1A, GABARAPL1, NAA10 TP53 4374/4885LMNA 1876/4885HTT 1790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.